| Today's Big NewsJul 21, 2023 |
| By Max Bayer Cidara Therapeutics has yet to hear whether Janssen is formally ending a collaboration on flu prophylaxis, saying it intends to trudge ahead with development until hearing otherwise. Janssen no longer lists the partnered asset in its pipeline. |
|
|
|
By James Waldron In a tricky financial climate, we’re increasingly used to hearing about biotechs reducing head count for their early-stage R&D work. But Passage Bio has decided to go in the other direction, laying off employees in its chemistry, manufacturing and controls group to prioritize its development strategy. |
By James Waldron Up to 500 roles at Idorsia are at risk as the Swiss biotech tries to halve its cash burn while it waits for its approved insomnia treatment Quviviq to pay off. |
Sponsored by Altasciences Optimize Your Drug Development Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drug development over other solid oral dosage forms? Find out! |
|
While individually inactive, these ingredients can cause unexpected drug interactions with both the drug they are administered with as well as co-medications... View Symposium Recording >>
|
|
By James Waldron Turnstone Biologics has brought in $80 million from its IPO in some welcome good news for a biotech looking to escape the shadow of abandoned Big Pharma partnerships. |
By Max Bayer,Gabrielle Masson Marc Tessier-Lavigne has resigned from his post as president of Stanford University after months of sidestepping allegations that select research he oversaw was manipulated. |
By Helen Floersh After shedding light on the cellular stress response, the researchers plan to pair their platform with artificial intelligence to identify druggable pathways, de-risking future clinical trials. |
By Teresa Carey This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines |
By Fraiser Kansteiner One of the world’s largest sterile injectables plants has landed in the path of a devastating act of nature. Wednesday, Pfizer said its manufacturing facility in Rocky Mount, North Carolina, suffered damage from a tornado. All of the company's employees are safe and accounted for. |
By Eric Sagonowsky Despite the widespread hype surrounding new and powerful obesity medicines, the drugs are still out of reach for many Americans who could benefit. A group of lawmakers is working to change that. |
By Conor Hale The miniature heart pump maker Abiomed—which J&J picked up last year for $16.6 billion—accounted for nearly a third of J&J's quarterly medtech gains. |
By Dave Muoio The influential Democrat's legislation is slated for committee markup next week, but is already being speared by Republicans for its price tag and hospitals for measures requiring site-neutral payments. |
By Zoey Becker Eisai showed off "promising" results from a modeling and bioavailability study of its subcutaneous Leqembi formulation. Astellas joined the growing list of drugmakers taking on the Inflation Reduction Act with legal action. GSK pulled two batches of its Nucala in Taiwan after glass particles were found in one vial. Plus more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the chemotherapy drug shortage, plus Grail’s harassment lawsuit and the rest of this week’s headlines |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more.
|
|
| WhitepaperLeading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WebinarDownload this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
| Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
